lobbying_activities: 2866470

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2866470	e42e9af8-789a-420e-9046-75be98444204	Q3	REGENXBIO	401105178	REGENXBIO	2022	third_quarter	CPT	Reform of Section 101 of the patent code including the Patent Eligibility Restoration Act, S. 4734. IP proposals related to drug pricing legislation including regulatory data protection for biologics, march in rights provisions of the Bayh-Dole Act, and Section 1498 of the patent code. S.1435/H.R. 2873/H.R. 2884 (patent thickening/product hopping) S.1425/H.R. 2883 (citizen petitions) S.1428/H.R.2891 (Rx patent settlements) Leahy-Cornyn Restoring the America Invents Act, PTAB reform bill. S.4430, Interagency Patent Coordination and Improvement Act of 2022 introduced by Sens. Durbin, Tillis, and Grassley.	HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Patent & Trademark Office (PTO),SENATE		70000	0	0	2022-10-15T21:41:39-04:00